Narayana Hrudayalaya cash flow

Latest FY26

Cash from operations: ₹1,618cr+63.5% on FY25
Capital spending: ₹875cr−18.5% on FY25
Free cash flow: ₹744cr−₹83.7 cr in FY25
Cash from financing: ₹2,343cr+340.6% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	449	278	242	210
	—	244	146	96.9	69.5
	—	−39.7	−20.7	−17.4	−10.0
	—	−26.5	12.2	11.1	39.2
	—	−20.4	−16.8	−47.2	−2.5
	—	−10.5	−10.1	−0.8	7.1
	—	4.6	−8.2	0.0	0.0
	—	−24.9	−0.3	−38.4	−11.7
	—	21.2	−149	26.4	−13.2
	—	−267	−6.0	15.9	−25.0
	—	−11.5	−101	−8.1	−12.3
	—	232	−186	256	53.9
	—	−49.8	252	−261	−25.1
	—	458	−29.1	−11.5	164
	—	65.6	37.1	−7.0	7.1
	—	1.5	−16.3	−13.3	−13.5
	—	−277	−23.2	16.3	−33.8
	—	−7.2	11.0	4.3	5.4
	—	33.1	3.0	6.1	4.7
	—	26.5	7.3	−0.9	5.2
Cash from operating activities
	1,005	974	936	889	752
	—	800	181	269	419
	—	1,774	1,116	1,158	1,170
	—	156	126	91.2	85.8
	—	1,618	990	1,067	1,085
Cash from investing activities
	—	875	1,074	971	522
	—	6.7	3.0	3.1	0.9
	—	0.0	0.0	0.0	80.0
	—	2,154	0.0	0.0	243
	—	19.0	16.4	18.1	7.6
	—	−649	−263	−509	−337
	—	−3,653	−1,317	−1,458	−1,174
Cash from financing activities
	—	0.0	0.0	0.0	0.1
	—	0.0	500	300	0.0
	—	2,946	505	523	277
	—	217	223	155	68.3
	—	128	52.6	56.2	57.2
	—	167	116	72.9	43.3
	—	91.0	81.2	50.8	20.3
	—	2,343	532	488	87.7
	—	308	205	97.1	−1.8
	—	5.2	0.7	0.0	−2.1
	—	313	205	97.1	−3.9
	—	761	—	242	145
Reference items
	1,749	1,617	1,276	1,152	966
	19.3%	20.5%	23.3%	23.0%	21.4%
	744	744	−83.7	96.0	563
	—	3,230	570	705	—
	₹36.38	₹36.38	−₹4.09	₹4.70	₹27.53
	47.12×	—	—	—	—
	—	2.01×	1.25×	1.35×	1.79×
	—	156	126	91.2	85.8
	—	167	116	72.9	43.3

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NH₹1,714.50

Narayana Hrudayalaya Ltd.

· Pharma & Health

₹ CrorePeersAPOLLOHOSP MAXHEALTH FORTIS NEULANDLAB NATCOPHARM LALPATHLAB SAILIFE COHANCEMcap ₹35,038 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	210.0	242.1	278.1	449.5	—
+ Finance Costs	69.5	96.9	146.4	243.7	—
+ Interest Income	-10.0	-17.4	-20.7	-39.7	—
+ Unrealised FX (Gain) / Loss	39.2	11.1	12.2	-26.5	—
+ Other Non-cash Items	-2.5	-47.2	-16.8	-20.4	—
+ Other — Cash Effects are Investing / Financing	7.1	-0.8	-10.1	-10.5	—
+ Other Reconciling Items	0.0	0.0	-8.2	4.6	—
Changes in Working Capital
+ Inventories	-11.7	-38.4	-0.3	-24.9	—
+ Trade Receivables — Current	-13.2	26.4	-149.0	21.2	—
+ Other Financial Assets — Current	-25.0	15.9	-6.0	-267.5	—
+ Other Financial Assets — Non-current	-12.3	-8.1	-100.8	-11.5	—
+ Other Current Assets	53.9	255.6	-186.0	231.8	—
+ Other Non-current Assets	-25.1	-260.9	252.1	-49.8	—
+ Trade Payables — Current	163.6	-11.5	-29.1	457.7	—
+ Other Financial Liabilities — Current	7.1	-7.0	37.1	65.6	—
+ Other Financial Liabilities — Non-current	-13.5	-13.3	-16.3	1.5	—
+ Other Current Liabilities	-33.8	16.3	-23.2	-277.1	—
+ Other Non-current Liabilities	5.4	4.3	11.0	-7.2	—
+ Provisions — Current	4.7	6.1	3.0	33.1	—
+ Provisions — Non-current	5.2	-0.9	7.3	26.5	—
Cash from Operating Activities
Profit Before Tax (per I/S)	751.6	888.5	935.5	974.4	1,005.4
+ Total Adjustments (incl. Working Capital)	418.7	269.3	180.8	799.9	—
Cash from Operations (pre-tax)	1,170.3	1,157.8	1,116.4	1,774.3	—
+ Income Taxes Paid	85.8	91.2	126.3	155.8	—
Cash from Operating Activities	1,084.6	1,066.6	990.1	1,618.5	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	522.0	970.6	1,073.8	874.9	—
+ Disp of Fixed Assets	0.9	3.1	3.0	6.7	—
+ Purchase of Investments (Equity / Debt)	80.0	0.0	0.0	0.0	—
+ Acq of Subsidiaries / Businesses (net)	243.3	0.0	0.0	2,154.5	—
+ Interest Received — Investing	7.6	18.1	16.4	19.0	—
+ Other Inflows / (Outflows) — Investing	-337.3	-508.5	-262.8	-649.5	—
Cash from Investing Activities	-1,174.1	-1,457.9	-1,317.1	-3,653.2	—
Cash from Financing Activities
+ Proceeds from Exercise of Stock Options	0.1	0.0	0.0	0.0	—
+ Proceeds from Debentures / Notes / Bonds	0.0	300.1	500.0	0.0	—
+ Proceeds from Borrowings	276.8	522.7	504.9	2,946.1	—
+ Repayment of Borrowings	68.3	154.5	223.2	217.3	—
+ Payment of Lease Liabilities	57.2	56.2	52.6	128.2	—
+ Interest Paid	43.3	72.9	116.0	166.7	—
+ Dividends Paid	20.3	50.8	81.2	91.0	—
Cash from Financing Activities	87.7	488.5	531.8	2,342.9	—
Net Changes in Cash (pre-FX)	-1.8	97.1	204.8	308.2	—
+ Effect of FX Rate Changes on Cash	-2.1	0.0	0.7	5.2	—
Net Changes in Cash	-3.9	97.1	205.4	313.4	—
Closing Cash	144.6	241.7	—	760.6	—
Reference Items
EBITDA	965.8	1,152.4	1,276.4	1,616.7	1,749.4
EBITDA Margin %	21.35	22.96	23.28	20.47	19.28
Free Cash Flow (CFO − Capex)	562.5	96.0	-83.7	743.5	743.5
Free Cash Flow to Equity	—	704.6	569.9	3,229.5	—
Free Cash Flow per Basic Share	27.53	4.70	-4.09	36.38	36.38
Price to Free Cash Flow	—	—	—	—	47.12
Cash Flow to Net Income	1.79	1.35	1.25	2.01	—
Cash Paid for Taxes	85.8	91.2	126.3	155.8	—
Cash Paid for Interest	43.3	72.9	116.0	166.7	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.